Quality of life in patients with AMD after laser stimulation of the retina with subsequent nutrient supplementation
DOI:
https://doi.org/10.31288/oftalmolzh201722532Keywords:
age-related macular degeneration, quality of life, laser stimulation of the retina, nutrient supplementationAbstract
Background: Previous studies of the psychological component of the quality of life (QoL) in patients with age-related maculopathy (ARM) and macular degeneration (AMD) have found that these patients were more likely to show signs of depression compared to older adults with good vision, which, along with their poor visual function, substantially worsened their QoL.
Purpose: To investigate the benefits of laser stimulation of the retina with subsequent 6-month daily nutrient supplementation for QoL in patients with ARM and AMD.
Materials and Methods: The study involved 34 patients (42 eyes; 16 (47%) male and 18 (53%) female; age, 47 years to 76 years) with ARM and dry AMD. Most of the patients were younger than 65 years. All study eyes received 10 every-day sessions of diode laser stimulation of the retina (LSR) (wavelength, 650 nm; irradiance, mW/cm2; treatment timing, 300 s). Thereafter, patients were administered one capsule of Nutrof® Total daily for 6 months. They completed the 25-item version of the National Eye Institute Visual Function Questionnaire (NEI VFQ-25) and Hospital Anxiety and Depression Scale (HADS) at baseline, immediately after a course of LSR, and after a subsequent 6-month course of nutrient supplementation.
Results: In 30 patients (88%), the mean percentage increase in visual acuity was 33.3% after a 6-month course of nutrient supplementation. The HADS scores decreased by 18% after a course of LSR (this decrease was significant), and by 21% after a subsequent 6-month supplementation with Nutrof® Total. The overall emotional distress score improved by 43.1% in 29 patients (85.3%) after a 6-month daily nutrient supplementation. There was a statistically significant improvement in NEI VFQ-25 overall composite following treatment (F=117.6; p=0.00001). This score increased to 70.1 immediately after a course of LSR, and to 76.4 after 6 months of supplementation with Nutrof® Total.
Conclusions: The comprehensive treatment (a course of laser stimulation of the retina with subsequent oral supplementation with Nutrof® Total) for ARM and dry AMD resulted in improved visual function, decreased anxiety and depression, and substantially improved QoL at the 6-month time-point.
References
1. Lee PP, Spitzer КА, Hays RD. The impact of blurred vision on functioning and well-being. Ophthalmology. 1997 Mar;104(3):390-6 https://doi.org/10.1016/S0161-6420(97)30303-0
2. Mihaila V, Enachescu D, Davila С. General Population Norms for Romania using the Short Form 36 Health Survey (SF-36). QoL Newsletter. 2000;26:17-8
3. Lisochkina AB, Kuznetsova TI. [Use of the NEI VFQ-25 for assessing QoL in patients with age-related macular degeneration]. Oftalmologicheskie vedomosti. 2010; 3(1):26-30 Russian
4. Yelin E. Measuring Functional Capacity of Persons with Disabilities in Light of Emerging Demands in the Workplace. Washington (DC): National Academies Press (US); 1999
5. Boiko EV, Sysoev VN, Novik A.A., Kuz'micheva OV. [Quality of life and psychological status of patients with glaucoma and cataract]. Glaucoma. 2010; 1:21-5 Russian
6. Orr P, Rentz AM, Margolis MK, et al. Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2011 May 18;52(6):3354-9 https://doi.org/10.1167/iovs.10-5645
7. Popescu ML, Boisjoly H, Schmaltz H, Kergoat MJ, et al. Explaining the relationship between three eye diseases and depressive symptoms in older adults. Invest Ophthalmol Vis Sci. 2012 Apr 24;53(4):2308-13 https://doi.org/10.1167/iovs.11-9330
8. Eramudugolla R, Wood J, Anstey KJ. Co-morbidity of depression and anxiety in common age-related eye diseases: a population-based study of 662 adults. Front Aging Neurosci. 2013 Oct 2;5:56 https://doi.org/10.3389/fnagi.2013.00056
9. Jivraj J, Jivraj I, Tennant М, Rudnisky С. Prevalence and impact of depressive symptoms in patients with age-related macular degeneration. Can J Ophthalmol 2013;48:269-73
https://doi.org/10.1016/j.jcjo.2013.03.007
10.Mathew RS, Delbaere К, Lord SR, et al. Depressive symptoms and quality of life in people with age- related macular degeneration. Ophthalmic Physiol Opt. 2011 Jul;31(4):375-80 https://doi.org/10.1111/j.1475-1313.2011.00848.x
11.Brody BL, Gamst AC, William RA, et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology. 2001;108:1893-900 https://doi.org/10.1016/S0161-6420(01)00754-0
12.Linnik LA, Usov NI, Baronetskaia IL et al. [Laser stimulation of the functional activity of ocular tissues. Abstracts of the 5th National Ophthalmological Congress of the USSR]. Tashkent, 25-29 September, 1979. Vol. 3. 126-7 p. Russian
13.McCusker MM, Durrani K, Payette MJ, Suchecki J. An eye on nutrition: The role of vitamins, essential fatty acids, and antioxidants in age-related macular degeneration, dry eye syndrome, and cataract. Clin Dermatol. 2016 Mar-Apr;34(2):276-85 https://doi.org/10.1016/j.clindermatol.2015.11.009
14.Sinn N, Milte CM, Street SJ, et al. Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Br J Nutr. 2012 Jun;107(11):1682-93 https://doi.org/10.1017/S0007114511004788
15.Novik AA, Ionova TI. [A guide for assessing quality of life in medical setting]. 2nd ed. Moscow: OLMA Media Group; 2007 Russian
16.Clemons TE, Chew EY, Bressler SB, McBee W. National eye institute visual function questionnaire in the age-related eye disease study (AREDS): Report No. 10. Arch Ophthalmol. 2003 Feb;121(2):211-7 https://doi.org/10.1001/archopht.121.2.211
17.Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001 Jul;119(7):1050-8 https://doi.org/10.1001/archopht.119.7.1050
18.Zigmond AS, Snaith RP. The Hospital Anxiety and Depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70 https://doi.org/10.1111/j.1600-0447.1983.tb09716.x
19.Karadeniz Ugurlu S, Kocakaya Altundal AE, Altin Ekin M. Comparison of vision-related quality of life in primary open-angle glaucoma and dry-type age-related macular degeneration. Eye (Lond). 2016 Nov 4. [Epub ahead of print]. https://doi.org/10.1038/eye.2016.219
20.Uauy R, Dangour AD. Nutrition in brain development and aging: role of essential fatty acids. Nutr Rev. 2006 May;64(5 Pt 2):S24-33 https://doi.org/10.1301/nr.2006.may.S24-S33
21.Lima VC, Rosen RB, Farah M. Macular pigment in retinal health and disease. Int J Retina Vitreous. 2016 Aug15;2:19 https://doi.org/10.1186/s40942-016-0044-9
22.Ma L, Yan SF, Huang YM, et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology. 2012 Nov;119(11):2290-7 https://doi.org/10.1016/j.ophtha.2012.06.014
23.Cheung LK, Eaton A. Age-related macular degeneration. Pharmacotherapy. 2013 Aug;33(8): 838-55 https://doi.org/10.1002/phar.1264
24.Augustin А, Sahel JA, Bandello F, et al. Anxiety and depression prevalence rates in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1498-503 https://doi.org/10.1167/iovs.06-0761
25.Ord LM, Wright J, DeAngelis MM, Feehan M. Quality of Life with Macular Degeneration Is Not as Dark as It May Seem: Patients' Perceptions of the MacDQoL Questionnaire. Clin Med. 2015 Sep 22;4(9):1841-52 https://doi.org/10.3390/jcm4091841
26.Taylor DJ, Hobby АЕ, Binns АМ, Crabb DP. How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review. BMJ Open. 2016 Dec 2;6(12):e011504 https://doi.org/10.1136/bmjopen-2016-011504
27.Tao Y, Jiang Р, Wei Y, et al. ?-Lipoic Acid Treatment Improves Vision-Related Quality of Life in Patients with Dry Age-Related Macular Degeneration. Tohoku J Exp Med. 2016;240(3):209-214 https://doi.org/10.1620/tjem.240.209
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 О. В. Гузун, А. Р. Король
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
